We label the strength of evidence and flag estimates as estimates never as clinical fact
Signos+ is the first and only program that pairs GLP1 medication with a CGM and app, so you can succeed
Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
Report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme at yellowcard.mhra.gov.uk
Healthcare providers increasingly rely on GLP-1 agonists in tandem with other diabetes and obesity interventions, to get better therapeutic results and steadier disease management
If you have a history of heart disease, diabetes, or other cardiovascular conditions, you might be at a higher risk for low blood pressure